SAB Biotherapeutics, Inc. (SABS) Fair Value 2026

SABS · Biological Products, (No Diagnostic Substances) ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.2 /10

32 fundamental signals · 13 models active

Value Trap Risk

WARN (53/100)

Quick Summary — As of 2026-07-15, SAB Biotherapeutics, Inc. (SABS) trades at $3.62, approximately 184% above CirclFi’s Bayesian DCF fair value of $1.28. QOC: 5.2/10. Value Trap Risk: 53/100 (WARN). 13/13 models active.

Key Facts

Ticker
SABS
Price
$3.62
Quality Score
5.2/10
Value Trap Risk
53/100
Models Active
13/13
Last Updated
Strength: 13 independent models provide multi-angle coverage
Risk: Value Trap score of 53 suggests caution despite apparent undervaluation

Is SAB Biotherapeutics, Inc. (SABS) Undervalued or Overvalued in 2026?

According to CirclFi’s 13-model valuation engine, SAB Biotherapeutics, Inc. (SABS) appears overvalued as of : the median of 13 independent fair value estimates is $1.86, 48.6% below the current price of $3.62. Estimates range from $0.22 to $4.85. SABS scores 5.2/10 on fundamental quality and 53/100 on value-trap risk.

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy SAB Biotherapeutics, Inc. Stock in 2026? →

Valuation Matrix

13 Intrinsic Value Models vs. Current Price ($3.62)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Medium Conviction
 $1.28 -64.7%
Earnings Power Value
Medium Conviction
 $1.86 -48.6%
CUCE Ensemble
Low Conviction
 $2.09 -42.2%
First Chicago
Low Conviction
 $0.61 -83.3%

Unlock the Full Matrix

Access 9 additional models including EROIC Spread, Markov DDM, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 13 Models →

Cancel anytime · No contracts · Instant access

What Is SAB Biotherapeutics, Inc. (SABS) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the balance of valuation evidence tilts cautious on SAB Biotherapeutics, Inc. at its current price of $3.62. The composite intrinsic value is estimated at $2.12 (-41.5% average return), with 9 models flagging overvaluation risk. The most optimistic model, Regime Cross, places fair value at $4.85 (+33.9%), while Sentiment SOTP — the most conservative — estimates $0.22 (-93.9%). This +127.8% gap reflects genuine analytical uncertainty about SAB Biotherapeutics, Inc.'s intrinsic worth.

What Do the Models Say About SABS?

13 of 13 models are currently active for SABS. Of these, 4 models suggest upside while 9 models suggest overvaluation. The Bayesian DCF estimates SABS's intrinsic value at $1.28, implying -64.7% downside from the current price. See which stocks rank higher →

How Does SABS Rank in Biological Products, (No Diagnostic Substances)?

Among 134 Biological Products, (No Diagnostic Substances) stocks, SABS ranks #70 by Quality of Company score. CirclFi's QOC score of 5.2/10 evaluates 32 fundamental signals. A score of 5.2 reflects mixed fundamentals.

See all Most Undervalued Biological Products, (No Diagnostic Substances) Stocks →

SAB Biotherapeutics, Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is SABS a Value Trap?

CirclFi's Value Trap algorithm assigns SABS a score of 53/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

13 of 13 models are active for SAB Biotherapeutics, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, SAB Biotherapeutics, Inc.'s fundamental quality profile registers 5.2/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +127.8% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every SABS valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across SABS's 13 active models, average confidence is 28%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy SAB Biotherapeutics, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biological Products, (No Diagnostic Substances) Stocks Should You Also Analyze?

8 related Biological Products, (No Diagnostic Substances) stocks with 13-model coverage

EXELExelixis, Inc.QOC 10.0HALOHalozyme Therapeutics, Inc.QOC 10.0NBIXNeurocrine Biosciences, Inc.QOC 10.0GILDGilead Sciences, Inc.QOC 9.7PLXProtalix BioTherapeutics, Inc. QOC 8.6BIIBBiogen Inc.QOC 8.4IMCRImmunocore Holdings plcQOC 7.9TECHBio-Techne CorpQOC 7.8

Read investment analysis: EXEL · HALO · NBIX · GILD · PLX

See all Biological Products, (No Diagnostic Substances) stocks ranked →

Frequently Asked Questions About SAB Biotherapeutics, Inc.

What is SAB Biotherapeutics, Inc.'s intrinsic value in 2026?

Based on CirclFi's 13-model analysis, SAB Biotherapeutics, Inc. (SABS) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $1.28. The Quality of Company score is 5.2/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is SABS overvalued or undervalued right now?

At $3.62, 4 of 13 active models suggest SABS may be undervalued, while 9 indicate potential overvaluation. The median of all 13 fair value estimates is $1.86, 48.6% below the current price of $3.62 — a consensus view that SABS is overvalued. The assessment depends on which methodology best fits SAB Biotherapeutics, Inc.'s business model in Biological Products, (No Diagnostic Substances).

What does a Quality of Company score of 5.2 mean for SABS?

SAB Biotherapeutics, Inc.'s QOC of 5.2/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on SABS?

CirclFi analyzes SABS with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 13 of 13 are active for this stock. Read the full methodology →

Is SABS a value trap in 2026?

SAB Biotherapeutics, Inc.'s Value Trap score is 53/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 13-model valuation engine, SAB Biotherapeutics, Inc. (SABS) has a median fair value of $1.86 — 48.6% below the current price of $3.62 — as of 2026-07-15.” Source: circlfi.com/stock/SABS/ · Methodology

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 13 mathematical frameworks give you clarity on SABS.

Unlock All 13 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access